153 related articles for article (PubMed ID: 19225536)
21. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
22. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.
Dal Col J; Dolcetti R
Cell Cycle; 2008 Sep; 7(18):2813-6. PubMed ID: 18769147
[TBL] [Abstract][Full Text] [Related]
23. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
24. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
25. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
Borthakur G; Duvvuri S; Ruvolo V; Tripathi DN; Piya S; Burks J; Jacamo R; Kojima K; Ruvolo P; Fueyo-Margareto J; Konopleva M; Andreeff M
PLoS One; 2015; 10(10):e0139254. PubMed ID: 26440941
[TBL] [Abstract][Full Text] [Related]
26. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
[TBL] [Abstract][Full Text] [Related]
27. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract][Full Text] [Related]
29. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
31. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
32. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases.
Zajkowicz A; Rusin M
Mech Ageing Dev; 2011; 132(11-12):543-51. PubMed ID: 21945951
[TBL] [Abstract][Full Text] [Related]
33. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
Feng Z; Hu W; de Stanchina E; Teresky AK; Jin S; Lowe S; Levine AJ
Cancer Res; 2007 Apr; 67(7):3043-53. PubMed ID: 17409411
[TBL] [Abstract][Full Text] [Related]
34. Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway.
Dreyer HC; Glynn EL; Lujan HL; Fry CS; DiCarlo SE; Rasmussen BB
J Appl Physiol (1985); 2008 Jan; 104(1):27-33. PubMed ID: 17885021
[TBL] [Abstract][Full Text] [Related]
35. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
36. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells.
Bhattacharya S; Ray RM; Johnson LR
Cell Signal; 2009 Apr; 21(4):509-22. PubMed ID: 19136059
[TBL] [Abstract][Full Text] [Related]
37. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression.
Igata M; Motoshima H; Tsuruzoe K; Kojima K; Matsumura T; Kondo T; Taguchi T; Nakamaru K; Yano M; Kukidome D; Matsumoto K; Toyonaga T; Asano T; Nishikawa T; Araki E
Circ Res; 2005 Oct; 97(8):837-44. PubMed ID: 16151020
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
40. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
